Research Explorer

Your browser does not support JavaScript or JavaScript is not enabled. Without JavaScript some functions of this webapplication may be disabled or cause error messages. To enable JavaScript, please consult the manual of your browser or contact your system administrator.

Project

Exploiting novel GR biology as an opportunity to develop safer anti-inflammatory drugs

Outputs and Outcomes

Acronym

SEGRM 2

Code

F2014/IOF-ADV/022

Duration

15 August 2014 → 31 March 2018

Funding

Regional and community funding: Industrial Research Fund

Promotor

Karolien De Bosscher

Research disciplines

Medical and health sciences
- Biomarker discovery and evaluation
- Drug discovery and development
- Medicinal products
- Pharmaceutics
- Pharmacognosy and phytochemistry
- Pharmacology
- Pharmacotherapy
- Toxicology and toxinology
- Other pharmaceutical sciences

Keywords

selective drug discovery Glucocorticoid receptor agonist

Project description

Exploiting novel GR biology as an opportunity to develop safer anti-inflammatory drugs

For reasons of confidentiality the project summary cannot be disclosed.

For more information please contact the (co)promoter.

English

Dutch

English

Cookie settings

In addition to functional cookies which are necessary for the website to function, Ghent University uses non-functional cookies such as statistical cookies and social media cookies. These non-functional cookies can also be placed by third parties, for example to measure the use of the site or to share content on social media. Certain media are only available if you accept the cookies. You can set and modify your cookie preferences yourself. Find out what cookies we use and why in the Cookie Statement.

Analytics

AnalyticsWe'll collect information about your visit to our site. It helps us understand how the site is used – what's working, what might be broken and what we should improve.

Powered by